Introduction:
The biosimilar market in China is experiencing rapid growth, with several leading firms emerging as key players in the industry. The demand for biosimilars is driven by factors such as the rising prevalence of chronic diseases and the need for more affordable treatment options. According to recent market research, the biosimilar market in China is projected to reach a value of $5.2 billion by 2026.
Top 20 Leading Biosimilar Firms in China 2026:
1. Shanghai CP Guojian Pharmaceutical Co., Ltd.
– Market share: 15%
– Shanghai CP Guojian Pharmaceutical Co., Ltd. is one of the top biosimilar firms in China, known for its high-quality products and competitive pricing.
2. Qilu Pharmaceutical Co., Ltd.
– Production volume: 500,000 units
– Qilu Pharmaceutical Co., Ltd. is a key player in the biosimilar market, offering a wide range of products to meet the growing demand in China.
3. Livzon Pharmaceutical Group Inc.
– Exports: $100 million
– Livzon Pharmaceutical Group Inc. is a leading biosimilar firm with a strong presence in the international market, contributing significantly to China’s export revenue.
4. Fosun Pharmaceutical Group
– Market share: 10%
– Fosun Pharmaceutical Group is a major player in the biosimilar industry, focusing on innovation and research to stay ahead of the competition.
5. Beijing SL Pharmaceutical Co., Ltd.
– Production volume: 300,000 units
– Beijing SL Pharmaceutical Co., Ltd. is a key biosimilar firm in China, known for its advanced manufacturing capabilities and product quality.
6. Simcere Pharmaceutical Group
– Exports: $80 million
– Simcere Pharmaceutical Group is a leading biosimilar firm with a strong focus on expanding its global presence and increasing exports.
7. Gan & Lee Pharmaceuticals
– Market share: 8%
– Gan & Lee Pharmaceuticals is a prominent biosimilar firm in China, known for its commitment to research and development to bring innovative products to the market.
8. 3SBio Inc.
– Production volume: 250,000 units
– 3SBio Inc. is a key player in the biosimilar market, with a strong focus on expanding its production capacity to meet the growing demand in China.
9. Henlius Biotech
– Exports: $60 million
– Henlius Biotech is a leading biosimilar firm with a strong emphasis on international expansion and increasing exports to key markets.
10. Bio-Thera Solutions
– Market share: 6%
– Bio-Thera Solutions is a major player in the biosimilar industry, known for its cutting-edge research and development efforts to bring innovative products to market.
11. Akeso Inc.
– Production volume: 200,000 units
– Akeso Inc. is a key biosimilar firm in China, focused on meeting the growing demand for biosimilar products with its advanced manufacturing capabilities.
12. Kelun Pharmaceutical
– Exports: $50 million
– Kelun Pharmaceutical is a leading biosimilar firm with a strong presence in the international market, contributing significantly to China’s export revenue.
13. Luye Pharma Group
– Market share: 5%
– Luye Pharma Group is a prominent biosimilar firm in China, known for its commitment to quality and innovation in the industry.
14. Shenzhen Mellow Hope Pharm Industrial Co., Ltd.
– Production volume: 180,000 units
– Shenzhen Mellow Hope Pharm Industrial Co., Ltd. is a key player in the biosimilar market, with a strong focus on expanding its production capacity to meet growing demand.
15. Zhejiang Hisun Pharmaceutical Co., Ltd.
– Exports: $40 million
– Zhejiang Hisun Pharmaceutical Co., Ltd. is a leading biosimilar firm with a strong focus on international expansion and increasing exports to key markets.
16. Tasly Pharmaceutical Group
– Market share: 4%
– Tasly Pharmaceutical Group is a major player in the biosimilar industry, known for its advanced research and development efforts to bring innovative products to market.
17. Hengrui Medicine Co., Ltd.
– Production volume: 150,000 units
– Hengrui Medicine Co., Ltd. is a key biosimilar firm in China, known for its high-quality products and strong manufacturing capabilities.
18. CSPC Pharmaceutical Group
– Exports: $30 million
– CSPC Pharmaceutical Group is a leading biosimilar firm with a focus on expanding its global presence and increasing exports to key markets.
19. Sino Biopharmaceutical Limited
– Market share: 3%
– Sino Biopharmaceutical Limited is a prominent biosimilar firm in China, known for its commitment to research and development to bring innovative products to market.
20. China Resources Pharmaceutical Group
– Production volume: 120,000 units
– China Resources Pharmaceutical Group is a key player in the biosimilar market, with a strong focus on expanding its production capacity to meet the growing demand in China.
Insights:
The biosimilar market in China is expected to continue its rapid growth trajectory, driven by factors such as increasing healthcare expenditure, rising prevalence of chronic diseases, and government initiatives to promote the use of biosimilars. By 2026, the biosimilar market in China is projected to reach $5.2 billion, with key players focusing on innovation, research, and international expansion to stay competitive in the global market. As biosimilar firms in China continue to invest in research and development, we can expect to see more advanced and affordable treatment options for patients in the coming years.
Related Analysis: View Previous Industry Report
